BTIG affirms Kite Pharma, Inc. (Nasdaq: KITE) with a Neutral rating after the company announced the first patient was enrolled ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE